Risankizumab outperforms secukinumab at one year

A phase 3b study investigating the efficacy and safety of risankizumab compared to secukinumab showed positive results, with risankizumab demonstrating noninferiority to secukinumab at week 16, and superiority at week 52. In the IMMerge phase 3b trial against secukinumab, risankizumab met both of its primary endpoints — noninferiority at week 16 and superiority at week … Leggi tutto